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Objectives: Surveillance of antibiotic consumption in the community is of utmost importance to inform and
evaluate control strategies. Data on two decades of antibiotic consumption in the community were collected
from 30 EU/European Economic Area (EEA) countries. This article reviews temporal trends and the presence of
abrupt changes in subgroups of relevance in antimicrobial stewardship.
Methods: For the period 1997–2017, data on yearly antibiotic consumption in the community, aggregated at
the level of the active substance, were collected using the WHO ATC classification and expressed in DDD (ATC/
DDD index 2019) per 1000 inhabitants per day. We applied a range of non-linear mixed models to assess the
presence of changes in the consumption of antibacterials for systemic use (ATC group J01) and eight antibiotic
subgroups.
Results: For the majority of the studied groups, a country-specific change-point model provided the best fit.
Depending on the antibiotic group/subgroup and on the country, change-points were spread out between 2000
and 2013.
Conclusions: Due to the heterogeneity in antibiotic consumption in the community across EU/EEA countries, a
country-specific change-point model provided the better fit. Given the limitations of this model, our recommen-
dation for the included countries is to carefully interpret the country-specific results presented in this article and
to use the tutorial included in this series to conduct their own change-point analysis when evaluating the impact
of changes in regulations, public awareness campaigns, and other national interventions to improve antibiotic
consumption in the community.
Introduction
Since their discovery, antibiotics have played an important role in
the treatment of bacterial infections. Access to effective antibiotics
remains of utmost importance in modern healthcare.1 However,
overuse and misuse of antibiotics have been identified as important
factors leading to the increase of bacterial resistance.2–5 Because
the therapeutic options for treatment of multidrug-resistant
bacterial infections are limited, they represent a major public
health threat with prolonged hospital stays, increased health
care costs and increased mortality.6–8 Therefore, surveillance of
antibiotic consumption in both the community (i.e. primary care
sector) and hospital setting is crucial in order to inform
and evaluate strategies for prevention and control of antibiotic
resistance.
In 2001, the European Commission funded the European
Surveillance of Antimicrobial Consumption (ESAC) project with the
aim of collecting comparable and reliable data on antibiotic
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consumption in Europe. In 2011, this surveillance activity contin-
ued as the European Surveillance of Antimicrobial Consumption
Network (ESAC-Net),9 managed and hosted by ECDC. Using data
collected through these surveillance networks, trends of antibiotic
consumption in the community (1997–2009) have been studied
for the different antibiotic subgroups.10–14 In 2013, Minalu et al.15
proposed a change-point model using a Bayesian framework to
improve model fit by allowing for abrupt changes in tetracycline
consumption. The approach suggested by Minalu et al.15 has
previously been used to update two series of articles on antibiotic
consumption in the community: 1997–200916–21 and 1997–
2003.10–14,22–27 In that update, statistical modelling focused on
assessing the occurrence of change-points from the EU/European
Economic Area (EEA) perspective, which is reflected by the use of
common change-point(s) for the participating countries. However,
when focusing on explaining as much of the observed variability as
possible, regardless of the perspective, other models, e.g. models
including country-specific change-points, might provide a better fit
to the data.
In this article, we apply a range of models to data collected
through ESAC and ESAC-Net on the consumption of antibacterials




The methods for collecting and analysing data on antibiotic consumption in
the community are described in the introductory article of this series.28
In summary, data on antibiotic consumption, aggregated at the level of
the active substance, were collected in accordance with the ATC classifica-
tion defined by the WHO Collaborating Centre for Drug Statistics
Methodology.29 Data on consumption expressed in DDD (ATC/DDD index
2019)29 per 1000 inhabitants per day were available for 30 EU/EEA coun-
tries for the period 1997–2017. To limit difficulties in model convergence,
countries that reported consumption data for <60% of the total number
of years included in the study (i.e. <13 years) were excluded from the
change-point analysis.
In this article, we focused on antibacterials for systemic use (ATC J01)
and eight specific subgroups: tetracyclines (J01A), b-lactamase-sensitive
penicillins (J01CE; narrow-spectrum penicillins) and b-lactamase-resistant
penicillins (J01CF; penicillinase-resistant penicillins), cephalosporins
(J01DB, J01DC, J01DD and J01DE), combinations of sulphonamides and
trimethoprim (J01EE), macrolides (J01FA), fluoroquinolones (J01MA),
penicillins with extended spectrum (J01CA; extended-spectrum penicil-
lins) and combinations of penicillins, including b-lactamase inhibitors
(J01CR; combinations of penicillins), and nitrofuran derivatives (J01XE).
These subgroups were selected because they represent first-line anti-
biotic treatments or are recommended for use in severe and multidrug-
resistant bacterial infections.30
Statistical analysis
In this manuscript, we focused on detecting changes in antibiotic
consumption by country, rather than on detecting common changes for
the EU/EEA as a whole. Therefore, the statistical analysis deviates slight-
ly from the approach followed in the other articles of this series.22,31
Rather than using quarterly data on antibiotic consumption, we used
the more complete yearly data for this manuscript. We considered
the following models that are discussed in detail in the tutorial of this
series:31
Model 1: Mixed model without change-points;
Model 2: Mixed model with one common change-
point (C1);
Model 3: Mixed model with two common change-points
(C1 and C2 with C1<C2);
Model 4: Mixed model with three common change-
points (C1, C2 and C3 with C1<C2<C3).
In addition, we considered the following model:
Model 5: Mixed model with one country-specific change-
point (ci),
where the common change-point (C1) from Model 2 was replaced by a
change-point for which the location is country-specific and data-driven
(ci). To reflect our lack of prior knowledge on the location of this country-
specific change-point, we used a uniform distribution over the whole
time range.15
Model selection was based on the Deviance Information Criterion
(DIC),32 with trace plots used to verify convergence of the fitted models.
Significance was based on 95% Bayesian credible intervals which are inter-
vals from the posterior distribution within which the unobserved parame-
ters fall with 95% probability.33 We assumed that the less complete series
were for countries that had not joined the network from its start, missed
intermittent data calls, or had not yet submitted their data for the more
recent years.
Results
The longitudinal profiles for the 30 EU/EEA countries demonstrated
that there was heterogeneity both between and within countries
(Figure 1). The lowest consumption of antibacterials for systemic
use (ATC J01) was recorded in the Netherlands in 2003 (8.72 DDD
per 1000 inhabitants per day) while the highest consumption was
recorded in Greece in 2008 (40.39 DDD per 1000 inhabitants per
day).
Countries reporting antibiotic consumption for <60% of the
included years (<13 years), i.e. Romania (8 years reported; commu-
nity and hospital sector combined), Cyprus (12 years reported;
community and hospital sector combined), Malta (11 years
reported) and Lithuania (12 years reported), were excluded from
further analysis in order to minimize convergence issues.
When modelling consumption data for antibacterials for
systemic use (ATC J01), the best model fit was obtained for a
model including country-specific change-points (Model 5; Table 1).
Consumption of antibacterials for systemic use significantly
increased, between 1997 and the country-specific change-point
for Denmark, Greece and Italy while it significantly decreased for
Bulgaria, France, Hungary and Iceland. After the change-point, a
significant increase was observed for Bulgaria, Poland, Spain (pri-
vate prescriptions included from 2016 onwards) and the United
Kingdom while a significant decrease was observed for Croatia,
Finland, Greece, Italy and Portugal. Change-points were located
between 2002 and 2013, with the majority of the countries’
change-points located around 2008 (Figure 2).
For tetracyclines (J01A), the best model fit was obtained for the
model containing two common change-points: one in 2004 and
one in 2011 (Model 3; Table 1). In 1997, tetracycline consumption
was estimated at 2.861 (SE 0.265) DDD per 1000 inhabitants per
day. In general, tetracycline consumption decreased over time
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(#0.054, SE 0.019, DDD per 1000 inhabitants per day per year) up
to 2004, after which it did not change significantly [!0.030, SE
0.030, DDD per 1000 inhabitants per day per year up to 2011, then
#0.013 (SE 0.029) DDD per 1000 inhabitants per day per year
afterwards]. Significant increases were observed between 1997
and 2004 for France, Germany and Ireland while significant
decreases were observed for Belgium, Bulgaria, Estonia, Finland,
Hungary, Luxembourg, Norway, Poland, Portugal and Slovenia.
Between 2005 and 2011, significant increases were observed for
Denmark, Finland, the Netherlands, Norway and the United
Kingdom while significant decreases were observed for Bulgaria,
Croatia, Czechia, Estonia, Germany, Greece, Hungary, Ireland,
Poland, Slovakia and Slovenia. After 2011, significant increases
were observed for Greece, Slovakia, Spain (private prescriptions
included from 2016 onwards) and the United Kingdom while sig-
nificant decreases were observed for Austria, Croatia, Denmark,
Estonia, Finland, Germany, Luxembourg, the Netherlands and
Sweden.
For narrow-spectrum and penicillinase-resistant penicillins
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Figure 1. Evolution of consumption of antibacterials for systemic use (ATC J01) in the community, expressed in DDD (ATC/DDD index 2019) per 1000
inhabitants per day for 30 EU/EEA countries, 1997–2017 (unlabelled lines).
Table 1. Deviance Information Criterion for the five models fitted to data on antibiotic consumption of antibacterials for systemic use (ATC J01) and













for the best model
J01 1892.15 1635.64 1519.93 NC 1518.59 2002–2013
J01A 145.93 #109.96 #313.71 NC #307.14 2004 and 2011
J01CE & J01CF 324.33 177.77 7.28 NC 115.45 2001 and 2006
J01DB to J01DE 257.59 42.79 #41.08 NC #97.67 2001–2013
J01EE #296.4 #526.29 NC NC #801.08 2001–2013
J01FA 888.84 236.97 167.86 NC #44.6 2000–2012
J01MA #102.15 #301.67 #345.56 NC #440.87 2001–2010
J01CA & J01CR 963.83 738.45 650.88 579.56 425.99 2005–2013
J01XE #172.27 #215.33 NC NC #310.22 2003–2012
Bold font indicates the best fitting model.
CP, change-point; NC, no convergence was obtained; J01, antibacterials for systemic use; J01A, tetracyclines; J01CE, narrow-spectrum penicillins;
J01CF, penicillinase-resistant penicillins; J01DB to J01DE, cephalosporins; J01EE, combinations of sulphonamides and trimethoprim; J01FA, macro-









ent_2/ii68/6328682 by 81728827 user on 20 O
ctober 2021
containing two common change-points: one in 2001 and one in
2006 (Model 3; Table 1). In 1997, consumption of narrow-spec-
trum and penicillinase-resistant penicillins was estimated at 1.980
(SE 0.347) DDD per 1000 inhabitants per day. In general, consump-
tion did not change significantly over time [#0.018, SE 0.040, DDD
per 1000 inhabitants per day per year up to 2001, then #0.077 (SE
0.071) DDD per 1000 inhabitants per day per year up to 2006, and
#0.045 (SE 0.084) DDD per 1000 inhabitants per day per year
afterwards]. Significant increases were observed between 1997
and 2001 for Denmark and Slovakia while significant decreases
were observed for Finland, Iceland and Poland. Between 2002 and
2006, significant increases were observed for Denmark and Greece
while significant decreases were observed for Bulgaria, Finland,
Germany, Iceland, Poland, Slovakia and Slovenia. After 2006, sig-
nificant increases were observed for Ireland and the United
Kingdom while significant decreases were observed for Croatia,
Denmark, Greece, Hungary, Iceland, Norway, Slovakia, Slovenia
and Sweden.
For the other subgroups, the best model fit was obtained for a
country-specific change-point model (Model 5, Table 1).
Consumption of cephalosporins (J01DB, J01DC, J01DD and J01DE)
significantly increased between 1997 and the country-specific
change-point for Greece and Poland while it significantly
decreased for Belgium, France, Hungary and Spain (private pre-
scriptions included from 2016 onwards). After the change-point, a
significant increase was observed for Bulgaria, Czechia, Germany,
Poland, Slovakia and Spain (private prescriptions included from
2016 onwards) while a significant decrease was observed for
Croatia, France, Greece and Luxembourg. Change-points were
located between 2001 and 2013, with the majority of the coun-
tries’ change-points located around 2008 (Figure 3).
Consumption of combinations of sulphonamides and trimetho-
prim (J01EE) significantly increased between 1997 and the coun-
try-specific change-point for Bulgaria while it significantly
decreased for Austria, Belgium, Czechia, Estonia, Finland, Greece,
Hungary, Iceland, Italy, Luxembourg, Poland, Portugal, Slovakia,
Slovenia and Spain (private prescriptions included from 2016 on-
wards). After the change-point, a significant increase was
observed for Slovakia while a significant decrease was observed
for Bulgaria, Poland and Slovenia. Change-points were located be-
tween 2001 and 2013, with the majority of the countries’ change-
points located around 2007 (Figure 4).
Consumption of macrolides (J01FA) significantly increased be-
tween 1997 and the country-specific change-point for Bulgaria,
Croatia, Estonia, Greece, Ireland, Poland, Portugal and Slovakia
while it significantly decreased for Belgium, Luxembourg and
Spain (private prescriptions included from 2016 onwards). After
the change-point, a significant increase was observed for Belgium,
Luxembourg, Spain (private prescriptions included from 2016 on-















































Figure 2. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of anti-
bacterials for systemic use (ATC J01) in the community obtained from fitting Model 5 on yearly data from 26 EU/EEA countries, 1997–2017. Dotted
lines indicate averages. Country labels in black indicate an increase in the trend after versus before the change-point. Country labels in purple indicate
a decrease in the trend after versus before the change-point. For Spain, private prescription data are included from 2016 onwards. Abbreviations: AT,
Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czechia; DK, Denmark; EE, Estonia; FI, Finland; FR, France; DE, Germany; EL, Greece; HU, Hungary; IS,
Iceland; IE, Ireland; IT, Italy; LV, Latvia; LU, Luxembourg; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; SK, Slovakia; SI, Slovenia; ES,
Spain; SE, Sweden; UK, United Kingdom.
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observed for Austria, Croatia, Denmark, Finland, Greece, Italy,
Norway and Portugal. Change-points were located between 2000
and 2012, with the majority of the countries’ change-points
located around 2008 (Figure 5).
Consumption of fluoroquinolones (J01MA) significantly
increased between 1997 and the country-specific change-point
for all participating countries except Croatia, Latvia, the
Netherlands, Portugal, Slovenia, Sweden and the United
Kingdom. After the change-point, a significant decrease was
observed for Czechia, France, Germany, Italy, Portugal and
Sweden. Change-points were located between 2001 and 2010,
with the majority of the countries’ change-points located
around 2006 (Figure 6).
Consumption of extended-spectrum penicillins and combina-
tions of penicillins (J01CA and J01CR) significantly increased be-
tween 1997 and the country-specific change-point for Belgium,
Greece, Italy, Luxembourg, Portugal and Spain (private prescrip-
tions included from 2016 onwards) while it significantly decreased
for Estonia, France, Hungary, Iceland and Slovakia. After the
change-point, a significant increase was observed for Croatia,
France, Greece, Iceland and Spain (private prescriptions included
from 2016 onwards) while a significant decrease was observed for
Belgium, Italy and Luxembourg. Change-points were located
between 2005 and 2013, with the majority of the countries’
change-points located around 2008 (Figure 7).
Consumption of nitrofuran derivatives (J01XE) significantly
increased between 1997 and the country-specific change-point
for Luxembourg and Poland while it significantly decreased for
Iceland. After the change-point, a significant increase was
observed for Czechia, Iceland, Poland and Slovenia. Change-points
were located between 2003 and 2012, with the majority of the
countries’ change-points located around 2008 (Figure 8).
Including a third change-point (Model 4) resulted in non-
convergence for all subgroups under study, indicating that the
maximum number of common change-points was two.15
Discussion
For the majority of the subgroups under study, the country-specific
change-point model (Model 5) provided the best fit. This is not
surprising given the heterogeneity in antibiotic consumption in
the community between EU/EEA countries. Previous studies
on antibiotic consumption in Europe have pointed out this hetero-
geneity between EU/EEA countries with marked North-to-South
and West-to-East gradients for both antibiotic consumption and
resistance.34
Data on tetracycline consumption in the community show that
there are two common change-points: one in 2004 and one in
2011. However, the evolution of tetracycline consumption over














































Figure 3. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of cepha-
losporins (ATC J01DB, J01DC, J01DD and J01DE) in the community obtained from fitting Model 5 on yearly data from 26 EU/EEA countries, 1997–
2017. Dotted lines indicate averages. Country labels in black indicate an increase in the trend after versus before the change-point. Country labels in
purple indicate a decrease in the trend after versus before the change-point. For Spain, private prescription data are included from 2016 onwards. AT,
Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czechia; DK, Denmark; EE, Estonia; FI, Finland; FR, France; DE, Germany; EL, Greece; HU, Hungary; IS,
Iceland; IE, Ireland; IT, Italy; LV, Latvia; LU, Luxembourg; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; SK, Slovakia; SI, Slovenia; ES,





















































Figure 4. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of combi-
nations of sulphonamides and trimethoprim (ATC J01EE) in the community obtained from fitting Model 5 on yearly data from 26 EU/EEA countries,
1997–2017. Dotted lines indicate averages. Country labels in black indicate an increase in the trend after versus before the change-point. Country
labels in purple indicate a decrease in the trend after versus before the change-point. For Spain, private prescription data are included from 2016 on-
wards. AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czechia; DK, Denmark; EE, Estonia; FI, Finland; FR, France; DE, Germany; EL, Greece; HU,
Hungary; IS, Iceland; IE, Ireland; IT, Italy; LV, Latvia; LU, Luxembourg; NL, the Netherlands; NO, Norway; PL, Poland; PT, Portugal; SK, Slovakia; SI,














































Figure 5. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of macrolides
(ATC J01FA) in the community obtained from fitting Model 5 on yearly data from 26 EU/EEA countries, 1997–2017. Dotted lines indicate averages. Country
labels in black indicate an increase in the trend after versus before the change-point. Country labels in purple indicate a decrease in the trend after versus
before the change-point. For Spain, private prescription data are included from 2016 onwards. AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czechia;
DK, Denmark; EE, Estonia; FI, Finland; FR, France; DE, Germany; EL, Greece; HU, Hungary; IS, Iceland; IE, Ireland; IT, Italy; LV, Latvia; LU, Luxembourg; NL, the
Netherlands; NO, Norway; PL, Poland; PT, Portugal; SK, Slovakia; SI, Slovenia; ES, Spain; SE, Sweden; UK, United Kingdom.
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and other decreasing, tetracycline consumption in the periods
1997–2004, 2005–2011 and 2012–2017. Similarly for narrow-
spectrum and penicillinase-resistant penicillins, two common
change-points were observed: one in 2001 and one in 2006.
However, in addition for this subgroup, the evolution over time was
country-specific.
For antibacterials for systemic use and for the remaining sub-
groups, models with one country-specific change-point provided a
better fit. These country-specific change-points were spread out
between 2001 and 2013. For most countries, the trend in antibiotic
consumption after the change-point remained quite close to the
general trend. However, exceptions were the steep decrease in
macrolide consumption in Greece after 2007 (Figure 5) and the
steep increase in consumption of extended-spectrum penicillins
and combinations of penicillins in Spain (private prescriptions
included from 2016 onwards) after 2013 (Figure 7). For macrolide
consumption, both increases and decreases in consumption were
observed with the largest increase reported for Spain (private pre-
scriptions included from 2016 onwards). Similarly for extended-
spectrum penicillins and combinations of penicillins, both increases
and decreases in consumption were observed with the largest de-
crease reported for Luxembourg.
Consumption of antibacterials for systemic use increased in
some countries, while it decreased in other countries, with the
largest increase reported for Spain (private prescriptions included
from 2016 onwards) and the largest decrease reported for Finland
(Figure 2). For cephalosporins, consumption increased for some
countries, while it decreased for other countries. The largest in-
crease was reported for Poland and the largest decrease for
Luxembourg (Figure 3). A limiting factor of the analysis of this sub-
group is that cephalosporin consumption data were pooled but
consumption of the different generations of cephalosporins may
have varied over time.24,35
For combinations of sulphonamides and trimethoprim (Figure
4) and fluoroquinolones (Figure 6), both increases and decreases
were observed for individual countries. The largest increases were
reported for Slovakia and Bulgaria, respectively, while the largest
decreases were reported for Slovenia and Portugal, respectively.
Fluoroquinolones are commonly used antibiotics, which are often
prescribed for non-approved conditions or inappropriately pre-
scribed for viral infections.26 Additionally, their use should be
restricted due to potential severe side-effects.36 The increasing
trend of fluoroquinolone consumption, particularly in Bulgaria and
Hungary suggests increasing inappropriate use of this important
group of antibiotics and is worrisome.34,37
For the nitrofuran derivatives (Figure 8), no significant change
was observed for most countries while a significant increase was













































Figure 6. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of fluoro-
quinolones (ATC J01MA) in the community obtained from fitting Model 5 on yearly data from 26 EU/EEA countries, 1997–2017. Dotted lines indicate
averages. Country labels in black indicate an increase in the trend after versus before the change-point. Country labels in purple indicate a decrease
in the trend after versus before the change-point. For Spain, private prescription data are included from 2016 onwards. AT, Austria; BE, Belgium; BG,
Bulgaria; HR, Croatia; CZ, Czechia; DK, Denmark; EE, Estonia; FI, Finland; FR, France; DE, Germany; EL, Greece; HU, Hungary; IS, Iceland; IE, Ireland; IT,
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related to more appropriate prescribing for urinary tract infections
as recommended by many guidelines or an increased interest in
nitrofuran derivatives to compensate for antibiotic resistance to
other commonly prescribed antibiotics such as fluoroquinolones
and combinations of sulphonamides and trimethoprim.38,39
However, the increase in consumption of nitrofuran derivatives
was only accompanied by a significant decrease in combinations
of sulphonamides and trimethoprim in Poland and Slovenia, but
not in Czechia or Iceland, and by a significant decrease in con-
sumption of fluoroquinolones for Czechia, but not for Slovenia,
Poland or Iceland. Another possible explanation for the increase in
nitrofuran derivatives could be over-the-counter availability of
nitrofurantoin in several countries.40
In order to explain why change-points occurred at specific
points in time, three elements should be considered. The first
element is the infection rate in consecutive years, with a low (or
high) infection rate resulting in low (or high) antibiotic consump-
tion. For example, when analysing yearly consumption data, one
calendar year may include zero, one or two seasonal influenza epi-
demics, which would affect antibiotic consumption. This could be
avoided by using quarterly data. Within the infection rate, we need
to consider both the bacterial and the viral infection rate as antibi-
otics are often inappropriately prescribed for viral infections, main-
ly respiratory tract infections during the winter months. This
element could be of particular interest to explain some of the
change-points observed for antibiotics that are often overused
during, for example, seasonal influenza epidemics.
A second element to be considered when explaining the loca-
tion of the change-points are actions such as public awareness
campaigns on prudent antibiotic use and antibiotic resistance,
shortages and imposed restrictions. These could occur at different
points in time for individual EU/EEA countries with the aim to re-
duce unnecessary antibiotic use and therewith the occurrence of
resistance.41 National evaluations of such campaigns have been
reported for Belgium and France.42–45 However, we recommend
that each country conducts an extensive review on its public
awareness campaigns to better understand the reported country-
specific change-points.
A third element to take into consideration when interpreting
the results of the change-point analysis is the change of package
size driven by companies’ packaging practices. In general, over the
years, pharmaceutical companies have increased the number of
doses per package, which, for some countries, may have had an ef-
fect on consumption rates when expressed in DDD per 1000 inhab-
itants per day.46–48
Because the change-point analysis detects the most significant
change in trend, care should be taken in comparing detected
change-points with previous research. Changing the number of
included countries could have an effect on the location of common












































Figure 7. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of
extended-spectrum penicillins and of combinations of penicillins combined (ATC J01CA and J01CR) in the community obtained from fitting Model 5
on yearly data from 26 EU/EEA countries, 1997–2017. Dotted lines indicate averages. Country labels in black indicate an increase in the trend after
versus before the change-point. Country labels in purple indicate a decrease in the trend after versus before the change-point. For Spain, private pre-
scription data are included from 2016 onwards. AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czechia; DK, Denmark; EE, Estonia; FI, Finland;
FR, France; DE, Germany; EL, Greece; HU, Hungary; IS, Iceland; IE, Ireland; IT, Italy; LV, Latvia; LU, Luxembourg; NL, the Netherlands; NO, Norway; PL,
Poland; PT, Portugal; SK, Slovakia; SI, Slovenia; ES, Spain; SE, Sweden; UK, United Kingdom.
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on the locations of both country-specific and common change-
points. Our recommendation for the included countries is to inter-
pret their results as presented in this article with caution and use
the tutorial included in this series to conduct a change-point ana-
lysis when evaluating changes in guidelines or regulations, public
awareness campaigns, or other national interventions.31
In conclusion, the heterogeneity of antibiotic consumption
across EU/EEA countries required country-specific change-points
to assess changes in consumption over the period 1997–2017.
However, given the above-mentioned limitations of a model con-
taining country-specific change-points, our recommendation is
that each individual country conducts its own analysis, based on
the tutorial in this series, with its own data and additional context-
ual information, e.g. influenza epidemics, awareness campaigns
and change in package size, when evaluating national inter-
ventions to improve antibiotic consumption in the community.
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Figure 8. Estimated country-specific trend after the change-point versus location of the country-specific change-point for the consumption of nitro-
furan derivatives (ATC J01XE) in the community obtained from fitting Model 5 on yearly data from 26 EU/EEA countries, 1997–2017. Dotted lines indi-
cate averages. Country labels in black indicate an increase in the trend after versus before the change-point. Country labels in purple indicate a
decrease in the trend after versus before the change-point. For Spain, private prescription data are included from 2016 onwards. For Ireland,
consumption of nitrofurantoin (J01XE01) was not included. AT, Austria; BE, Belgium; BG, Bulgaria; HR, Croatia; CZ, Czechia; DK, Denmark; EE, Estonia;
FI, Finland; FR, France; DE, Germany; EL, Greece; HU, Hungary; IS, Iceland; IE, Ireland; IT, Italy; LV, Latvia; LU, Luxembourg; NL, the Netherlands;
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